CRMD CorMedix Inc. PHARMACEUTICAL PREPARATIONS Best Pharmaceutical Stocks 2026 →

CorMedix (CRMD) Stock: Buy, Sell, or Hold?

$4.92
+0.25 (+5.47%) ▲
5d: -10.15% 30d: -32.3% 90d: -39.84%
QUANTITATIVE VERDICT
HOLD
LOW Confidence (95%)
Quality Score
53/100
Position
OVERSOLD
30-Day Fair Range
$5.42 – $7.83
Position: OVERSOLD
Forward P/E & Valuation
49.1x CHEAP
vs 59.9x historical avg
Wall Street Target
$15.60
+234.8% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$4.65 / $5.79
Trend: Downtrend
💡Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 HOLD: CRMD shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.

Get Alerted When CRMD Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

In-depth Analysis How we analyze

Valuation Analysis: CRMD is currently trading at $4.92, which is considered oversold relative to its 30-day fair value range of $5.42 to $7.83. From a valuation perspective, the stock is trading at a discount (Forward PE: 49.0) compared to its historical average (59.9). Remarkably, the market is currently pricing in an annual earnings decline of 6.5% over the next few years. This pessimistic expectation contrasts with the company's recent 6.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.

Technical Outlook: Technically, CRMD is in a downtrend. Immediate support is located at $4.65, while resistance sits at $5.79. The stock is showing strong short-term momentum, up 5.5% recently.

Market Sentiment: CRMD scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $15.60 (+234.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.

Quick Decision Summary

Current Position OVERSOLD
Historical Trading Range $5.42 - $7.83
Company Quality Score 53/100 (HOLD)
Volume Confirmation HIGH
Confidence Score 95.2%

Trading Range & Key Levels

30-Day Trading Range $5.42 - $7.83
Current vs Trading Range OVERSOLD
Support Level $4.65
Resistance Level $5.79
Current Trend Downtrend
Technical data as of Nov 16, 2026

Protect Your Profits

Holding CRMD? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

Institutional Signals, 13F Whale Activity & Setup Structure

Quantitative Research Feed
Active Quantitative Risk Vetoes (1)
Attention Chase Risk: msg spike z=2.0 (24 vs ~9/day), 5d move -6.4%
Phase & Gamma Walls BREAKDOWN
Days in Phase: 109d (53% conf)
Technical Setup Structure MONITORING
Absorption: Inactive (CMF -0.24)
Pullback / Drawdown: -58.4% from 52W High
Consolidation: Trending (ADX 32.9)

Quantitative Signal Breakdown

  • BULLISH: Price oversold vs 30-day range
  • BULLISH: Strong technical setup (60/100)
  • BULLISH: High volume confirmation
  • BULLISH: Strong upward momentum (+5.5%)
  • BULLISH: Trading 234.8% below Wall St target ($15.60)
  • CAUTION: Bottoming setup, but lagging the sector by 19% over 20 days — wait for relative strength
  • CAUTION: 5-day price weakness (-10.1%) - monitor closely

Fundamental Context

Forward P/E (Next Year Est.) 49.05
Wall Street Target $15.60 (+234.8%)
Revenue Growth (YoY) -47.7%
Earnings Growth (YoY) 6.7%
Profit Margin 15.5%
Valuation Discount vs History -6.5% cheaper
PE vs Historical 49.1 vs 59.9 CHEAP
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): -6.5% (market-implied from PE analysis)
1-Year Target $4.36 (-7%)
2-Year Target $4.07 (-13%)
3-Year Target $3.81 (-18%)
3-Yr Target (if PE normalizes) (PE: 49→60) $4.65 (0%)
3-Year Scenarios Using analyst projected EPS growth
Bull: (PE: 49.1, Growth: -82.5%) $3.40 (+-27%)
Base: (SPY PE: 19.9, Growth: -82.5%) $1.38 (-71%)
Bear: (PE: 16.9, Growth: -82.5%) $1.17 (-75%)
📈 Valuation based on Current Earnings
Trailing PE: 2.36 | Current EPS (TTM): $2.05
Bull Case $2.66 (-43%)
Analyst growth -50.0%, PE expands to 2.6
Base Case $2.42 (-48%)
Market implied -50.0%, PE stable at 2.4
Bear Case $3.29 (-29%)
Severe decline -20.0%, PE contracts to 2.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡 Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 49.1 to 59.9
Stabilization Target: $5.69 (+22.1%)
PE Expansion Potential: +22.1%
Share CRMD Analysis

Share this live CRMD analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.

bloggers & journalists: you are free to use our charts with attribution.

Reddit & Retail Trader Sentiment (CRMD)

Bullish 12 Retail Mentions
Reddit / WSB Comments
1
Bearish
StockTwits Volume
11 msgs
24h retail stream
Last Tracked
Nov 16, 2026
Daily AI digest
AI Retail Discussion Summary: StockTwits messages show overwhelmingly bullish sentiment towards $CRMD, with several traders expressing confidence in the stock after the CEO's recent large purchase of shares.
Key Retail Themes: CEO buying Insider buying
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams. View All Trending Reddit & WSB Stocks →
Last updated: November 16, 2026 1:55 PM ET
Data refreshes hourly during market hours. Next update: 2:55 PM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL

Unlock Insider Activity

See real-time buying/selling by company executives for CRMD.

Create Free Account

Already have an account? Log In

Top Rated Biotechnology Stocks

Top-rated stocks in Biotechnology by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
ALNY
Alnylam Pharmaceuticals …
STRONG BUY
30 analysts
$300 60 HOLD
VRTX
Vertex Pharmaceuticals I…
STRONG BUY
32 analysts
$595 35 SELL
ASND
Ascendis Pharma AS
STRONG BUY
21 analysts
$315 34 SELL
IDYA
Ideaya Biosciences Inc
STRONG BUY
16 analysts
$51 60 BUY
PVLA
Palvella Therapeutics, I…
STRONG BUY
16 analysts
$234 49 HOLD

Advanced CRMD Option Strategies

Professional options setups generated by AI based on today's CRMD price and gamma walls.

Iron Condor Bull Call Bear Put Collar
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals